Register for our free email digests:
Opus Medical Inc.
Division of Smith & Nephew PLC
Latest From Sumitomo Dainippon Pharma Co. Ltd.
Analyst speculates that Gilead could move to acquire Spring Bank if combo trial yields promising data for functional cure of hepatitis B. Eisai in-licenses PARP inhibitor with potential in breast cancer from Oncology Venture, while Sunovion out-licenses three corticosteroid products to Covis.
Servier and Transgene will collaborate to apply viral vector technology to the development of CAR-T therapeutics, while Chinese vaccine maker Sinovac is taken private by an investment consortium.
GSK's deal with Exscientia will see the Scottish artificial intelligence pioneer discover new small molecules against targets selected by the big pharma. Exscientia is already working with Sanofi, Evotec, Sumitomo Dainippon Pharma and Sunovion across a range of disease areas, and is in talks with others.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Smith & Nephew PLC
- Senior Management
James W Hart, Pres. & CEO
Robert J Morocco, CFO
Allan Weinstein, VP, Sales
Norman S Gordon, VP, Product Dev.
Ed L Chang, VP, Mktg.
- Contact Info
Opus Medical Inc.
Phone: (949) 234-0400
27127 Calle Arroyo, Ste. 1924
San Juan Capistrano, CA 92675
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.